Synthorx: Sanofi Completes Acquisition of Synthorx, Inc.
Sanofi (NASDAQ: SNY; EURONEXT: SAN) announced today the successful completion of its acquisition of Synthorx, Inc. ("Synthorx") for $68 per share in cash.
Read full article »
Synthorx develops and commercializes novel protein therapeutics for the treatment of cancer, immune-oncology and autoimmune disorders.
Read more